A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
18 19 20 21 22 Antonio Llinas Antonio.Llinas@astrazeneca.com 23 Rafel Prohens email@example.com 24 25 26 27 28 ABSTRACT: 29 30 The discovery and detailed characterization of several new solid forms of a novel selective inhaled JAK-31 STAT inhibitor are described. Using a holistic cocrystallization screen approach to explore its 32 formulation landscape, we decrease the risk of future potential development failures due to a nonoptimal 33 pharmacokinetic lung profile or undesired lung effects indoi:10.1021/acs.cgd.8b01492.s001 fatcat:u4dxalrhi5d63hbo7kuyrabgf4